AKT1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ARAF is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 5 clinical trials for thyroid gland carcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRAF status and thyroid gland carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

CRKL is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

KRAS is an inclusion eligibility criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP3K1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAPK1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NF1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

PAX8 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PAX8 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPARG is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPARG status and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RET status and thyroid gland carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

Pralsetinib and selpercatinib have evidence of efficacy in patients with RET mutation in thyroid gland carcinoma [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

STK11 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].